Medicus Pharma
Highly Engaged Employees
Highly Engaged EmployeesHolding Companies & Conglomerates · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 Conshohocken State Rd Ste 200, Consh...Phone Number
(610) 636-0184Website
www.medicuspharma.comRevenue
-Stock Symbol
MDCXIndustry
ZI Rank: 3
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
5
5
3
About Medicus Pharma
Medicus Pharma Ltd is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials. Through the company's diverse experience and extensive industry network, the company is building Medicus into a leading pharmaceutical holding company, committed to delivering better treatment outcomes and alleviate pain and suffering. Utilizing a thesis driven collaborative process, the company identify, acquire and advance relatively de-risked clinical stage assets through clinical development and commercialization.Explore more
Medicus Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medicus Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Medicus Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Medicus Pharma
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Medicus Pharma launches new products
Earning: See what the market has to say on Medicus Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Medicus Pharma is spiking on competitors!
Check if Medicus Pharma has recently received funding, and reach out quickly before it becomes old news!
Medicus Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Medicus Pharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Medicus Pharma is experiencing very low activity levels compared to other companies in the Holding Companies & Conglomerates sector.
What does this means?
Medicus Pharma is drawing exceptional interest within the Holding Companies & Conglomerates industry, suggesting notable developments or strong market momentum, learn more about Medicus Pharma.
Medicus Pharma financials insights
Gather financial insights about Medicus Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$8M
2026
Debt
$22M
Medicus Pharma Tech Stack
A closer look at the technologies used by Medicus Pharma
See more technologies
Most Recent Scoops
Funding
Funding
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Lateral Move
Executive Move
Executive Moves, Lateral Move
Medicus Pharma News & Media
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine therapy for women with endometriosis Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine therapy for women with endometriosisMedicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix
Medicus Pharma (NASDAQ:MDCX) has filed a substantial modification application through the European Union Clinical Trials Information System to advance a Phase 2b study of its prostate cancer treatment Teverelix, the company said on Monday. The planned trial will focus on patients with...Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunityMedicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries
Read more news
Top Holding Companies & Conglomerates Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Medicus Pharma
Sign Up For FreeTo access detailed company insights
Medicus Pharma Ltd is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials. Through the company's diverse experience and extensive industry network, the company is building Medicus into a leading pharmaceutical holding company,... Read More
